---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-073561"
form_type: "8-K"
ticker: "KYMR"
cik: "0001815442"
company_name: "Kymera Therapeutics, Inc."
filed_at: "2026-02-26T23:59:59+00:00"
generated_at: "2026-05-15T23:45:46.532729+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Kymera Therapeutics enters $500M at-the-market offering agreement with TD Cowen

## Summary
- Agreement allows Kymera to sell up to $500M of common stock through TD Cowen at its discretion.
- TD Cowen will receive up to 3.0% commission on gross proceeds from sales under the agreement.
- Kymera terminated its prior Open Market Sale Agreement with Jefferies LLC effective February 26, 2026.
- Kymera filed a resale prospectus for up to 18,819,826 shares and 12,565,253 warrant shares held by certain stockholders.
- The resale filing does not guarantee any sales and Kymera will not receive proceeds from resales by stockholders.

## SEC filing metadata
- accession: 0001193125-26-073561
- form_type: 8-K
- ticker: KYMR
- cik: 0001815442
- company_name: Kymera Therapeutics, Inc.
- filed_at: 2026-02-26T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 1.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815442/000119312526073561/0001193125-26-073561-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815442/000119312526073561/d114045d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-073561
- JSON: https://secwatch.observer/filing/0001193125-26-073561.json
- Plain text: https://secwatch.observer/filing/0001193125-26-073561.txt

## Key facts
- Material Agreements
  Kymera Therapeutics, Inc. entered into TD Cowen Sales Agreement with TD Securities (USA) LLC valued at up to $500,000,000 (effective 2026-02-26).
  - Action: entry
  - Agreement: atm program
  - Counterparty: TD Securities (USA) LLC
  - Value: up to $500,000,000
  - Effective: 2026-02-26
  source text: On February 26, 2026, Kymera Therapeutics, Inc. (the “Company”) entered into a Sales Agreement (the “TD Cowen Sales Agreement”), with TD Securities (USA) LLC (“TD Cowen”) with respect to an “at-the-market” offering program under which the Company may issue and sell, from time to time at the Company’s sole discretion, shares of the Company’s common stock, having an aggregate offering price of up to $500,000,000 (the “Shares”), through TD Cowen.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1815442/000119312526073561/0001193125-26-073561-index.htm
- Material Agreements
  Kymera Therapeutics, Inc. terminated Open Market Sale Agreement SM with Jefferies LLC (effective 2026-02-26).
  - Action: termination
  - Agreement: atm program
  - Counterparty: Jefferies LLC
  - Effective: 2026-02-26
  source text: On February 26, 2026, Jefferies LLC (“Jefferies”) acknowledged and accepted the Company’s prior written notice to terminate the Open Market Sale Agreement SM , dated as of October 31, 2024, by and between the Company and Jefferies, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1815442/000119312526073561/0001193125-26-073561-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.